PIMCO Target Is on the Mark in 2000
The fund's new manager is making headway in a volatile market.
In a topsy-turvy year for mid-cap growth funds, this one has held up relatively well. PIMCO Target (PTAAX) has returned 15.9% for the year to date through December 8, 2000, which beats 84% of its peers. When combined with 1999’s above-average performance, new manager Jeff Parker is well on his way to establishing a solid record here.
Recently, though, the fund has struggled because of its technology holdings. In particular, stakes in semiconductor, fiberoptic, and contract-manufacturing companies have hurt during the autumn sell-off. For instance, chip maker PMC-Sierra (PMCS) has lost nearly half its value since September, while Jabil Circuit (JBL), which manufactures printed circuit boards, has gotten hit when PC makers such as Dell (DELL) have indicated slowing growth. Meanwhile, the fund’s health-care stake has nearly doubled in the last couple of months. Parker has added to names such as Quest Diagnostics (DGX). Others, such as medical-device maker Cytyc (CYTC), have had good runs lately. Overall, the fund lags the typical mid-growth peer during the trailing three-month period.
Brian Portnoy does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.